Aqua Medical
Aqua Medical is advancing therapy for type 2 diabetes with disruptive, vapor-based endoscopic ablation therapy. They have developed a platform technology that uses heated water vapor delivered through an endoscope to treat gastrointestinal diseases, including type 2 diabetes, in outpatient settings. Their technology aims to be faster, easier, and more effective than current management techniques, with a focus on improving glycemic control and reducing healthcare costs.
Industries
Nr. of Employees
small (1-50)
Aqua Medical
Patents
Vapor-based ablation treatment methods with improved treatment volume vapor management
US-12279803-B2
View DetailsVapor-based ablation treatment methods with improved treatment volume vapor management
US-11864809-B2
View DetailsMulti-stage vapor-based ablation treatment methods and vapor generation and delivery systems
US-11806066-B2
View Details
Vapor-based ablation treatment methods with improved treatment volume vapor management
US-12279803-B2
View DetailsVapor-based ablation treatment methods with improved treatment volume vapor management
US-11864809-B2
View DetailsMulti-stage vapor-based ablation treatment methods and vapor generation and delivery systems
US-11806066-B2
View DetailsProducts
Through-the-endoscope radiofrequency vapor ablation system
A platform system consisting of a radiofrequency vapor generator and interchangeable catheters intended to deliver heated water vapor via an endoscope for mucosal ablation across gastrointestinal sites.
Through-the-endoscope radiofrequency vapor ablation system
A platform system consisting of a radiofrequency vapor generator and interchangeable catheters intended to deliver heated water vapor via an endoscope for mucosal ablation across gastrointestinal sites.
Services
Sponsor and manage clinical studies evaluating safety, tolerability, and effectiveness of endoscopic vapor ablation therapies; includes study registration, site execution, and dissemination of results.
Execution or sponsorship of porcine model studies to evaluate device safety, tissue interactions, and procedural feasibility for endoscopic vapor ablation systems.
Sponsor and manage clinical studies evaluating safety, tolerability, and effectiveness of endoscopic vapor ablation therapies; includes study registration, site execution, and dissemination of results.
Execution or sponsorship of porcine model studies to evaluate device safety, tissue interactions, and procedural feasibility for endoscopic vapor ablation systems.
Expertise Areas
- Endoscopic ablation therapy development
- Interventional endoscopy
- Clinical trial management and clinical operations
- Preclinical safety and efficacy testing (large-animal models)
Key Technologies
- Radiofrequency-generated water vapor ablation
- Endoscopic delivery systems
- Catheter-based mucosal ablation devices
- Fluoroscopy-free endoscopic procedures
News & Updates
A study published in AJG in October 2024 reports that radiofrequency vapor ablation is safe and well-tolerated for duodenal mucosal ablation in treating type 2 diabetes, with six-month results from the first-in-human dose finding study.
A study published in UEG Journal in October 2024 investigates the safety, tolerability, and effectiveness of RF vapor ablation for duodenal mucosal ablation in managing type-2 diabetes.
A study published in Gut in June 2024 evaluates the safety and utility of RFVA in a porcine model for duodenal mucosal ablation.
A study published in Gut in June 2024 reports the first clinical application of a novel duodenal mucosal ablation device for type 2 diabetes.
A study published in DDW 2024 in May 2024 evaluates the safety and utility of RFVA in a porcine model for T2D.
A study published in GIE Journal in May 2024 assesses the safety and utility of RFVA in a porcine model for T2D.
A study published in AJG in October 2024 reports that radiofrequency vapor ablation is safe and well-tolerated for duodenal mucosal ablation in treating type 2 diabetes, with six-month results from the first-in-human dose finding study.
A study published in UEG Journal in October 2024 investigates the safety, tolerability, and effectiveness of RF vapor ablation for duodenal mucosal ablation in managing type-2 diabetes.
A study published in Gut in June 2024 evaluates the safety and utility of RFVA in a porcine model for duodenal mucosal ablation.
A study published in Gut in June 2024 reports the first clinical application of a novel duodenal mucosal ablation device for type 2 diabetes.
A study published in DDW 2024 in May 2024 evaluates the safety and utility of RFVA in a porcine model for T2D.
A study published in GIE Journal in May 2024 assesses the safety and utility of RFVA in a porcine model for T2D.